As advised via PHARMAC Tender Results of 30 April 2019 there is to be dual listing of Cetomacrogol with glycerol cream from 1 October 2019 to 29 February 2020. From 1 March 2020 BNM product will be sole supply.

New listing 1 October 2019

Cetomacrogol Crm 90% with glycerol 10% 500 ml OP Boucher                                 Pharmacode 2567709                     Schedule price $2.35

Cetomacrogol Crm 90% with glycerol 10% 1000 ml OP Boucher                                          Pharmacode 2567717                  Schedule price $3.10

Incumbent

Sorbolene with glycerin Pharmacy Health 500 ml OP                                                   Pharmacode 2366819                    Schedule price $2.82

Sorbolene with glycerin Pharmacy Health 1,000 ml OP                                                Pharmacode 2366827                    Schedule price $3.87

In order to have a smooth transition from one to the other and supporting the incumbent supplier to move their existing stock through the supply chain we will continue to supply only Pharmacy Health 1000 ml until supplies are depleted or 29 February 2020, whichever comes first. We do have stock of the new BNM brand should you feel very strongly that you need to change. To do this you will need to place your order via one of our CS team. We apologise for any inconvenience caused by this decision.

The 500 ml presentation has already switched as stocks are depleted.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 March 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close